

Trust is Earned

125,000
Devices
Distributed



Proven long-term outcomes across all etiologies through five years

The Conformable GORE® TAG® Device has demonstrated long-term freedom from device-related reintervention (93.1%) and low complication rates (zero migrations, fractures, or compressions).

Aneurysm, Transection, All Type B Dissection

THROUGH FIVE-YEAR
FOLLOW-UP*

(N = 217)

Procedural survival	100%	Spinal cord ischemia	3.7%	Fracture	0%
30-day survival	95.4%	Paraplegia	0.5%	Compression	0%
Freedom from device-related reintervention	93.1%	Aortic rupture associated with treated area	1.8%	Migration	0%

* Consolidated outcomes following 5 years of follow-up in TAG 08-01, TAG 08-02, and TAG 08-03 clinical studies.



Continuing with a legacy of firsts, the GORE® TAG® Device family **was the first** to reach 100,000 devices distributed worldwide. The Conformable GORE® TAG® Device has **proven** to be a safe, effective, and durable solution, earning the trust of physicians worldwide.

Gore TEVAR Leadership		
<p>1st approved device</p>	<p>1st approved device</p>	<p>20 year</p>
<p>in the U.S., Europe, and Japan</p>	<p>for endovascular treatment of aneurysm, transection, and Type B dissection</p>	<p>clinical history</p>

INDICATIONS FOR USE IN THE US: The GORE® TAG® Thoracic Endoprosthesis is intended for endovascular repair of all lesions of the descending thoracic aorta, including: Isolated lesions in patients who have appropriate anatomy, including: adequate iliac / femoral access, aortic inner diameter in the range of 16–42 mm, ≥ 20 mm non-aneurysmal aorta proximal and distal to the lesion; Type B dissections in patients who have appropriate anatomy, including: adequate iliac / femoral access, ≥ 20 mm landing zone proximal to the primary entry tear; proximal extent of the landing zone must not be dissected, diameter at proximal extent of proximal landing zone in the range of 16–42 mm. **CONTRAINDICATIONS:** Patients with known sensitivities or allergies to the device materials; patients who have a condition that threatens to infect the graft. Refer to *Instructions for Use* at goremedical.com for a complete description of all warnings, precautions, and adverse events. **INDICATIONS FOR USE UNDER CE MARK:** The GORE® TAG® Thoracic Endoprosthesis is indicated for endovascular repair of the descending thoracic aorta. **CONTRAINDICATIONS:** Patients with known sensitivities or allergies to the device materials; patients with a systemic infection who may be at increased risk of endovascular graft infection. Refer to *Instructions for Use* at goremedical.com for a complete description of all warnings, precautions, and adverse events. Rx Only

Products listed may not be available in all markets.

GORE®, TAG®, and designs are trademarks of W. L. Gore & Associates.
© 2016, 2017 W. L. Gore & Associates, Inc. AV1566-EN4 DECEMBER 2017



W. L. GORE & ASSOCIATES, INC.
Flagstaff, AZ 86004

+65.67332882 (Asia Pacific)
00800.6334.4673 (Europe)
800.437.8181 (United States)
928.779.2771 (United States)

goremedical.com